Figure 6.

Study summary: A high-throughput analysis of 184 proteins across diverse stages of RA (early and established disease) uncovered a consistently altered pattern, indicating potential diagnostic biomarkers, including CTSL1, SORT1, SAA4, TNFRSF10A, ST6GAL1, and CCL18. Methotrexate was administered to early RA patients, while tofacitinib was employed for established RA cases. Post a 6-month treatment period, the levels of proteins exhibiting alterations in both early and established RA were modulated, pinpointing susceptible proteins that may serve as candidate biomarkers indicative of the response to therapy. Annotated names of abbreviated proteins ( Supplementary Table 1 ). RA, rheumatoid arthritis; HDs, healthy donors; AUC, area under the curve.